Monitoring of the immunogenic response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers with Snibe SARS-CoV-2 S-RBD IgG chemiluminescent immunoassay
| Errataetall: |
CommentOn: Clin Chem Lab Med. 2021 Apr 14;59(8):1444-1452. - PMID 33855843 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
Clinical chemistry and laboratory medicine - 59(2021), 10 vom: 27. Sept., Seite e377-e379 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Salvagno, Gian Luca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies |
|---|
| Anmerkungen: |
Date Completed 08.09.2021 Date Revised 05.07.2022 published: Electronic-Print CommentOn: Clin Chem Lab Med. 2021 Apr 14;59(8):1444-1452. - PMID 33855843 Citation Status MEDLINE |
|---|
| doi: |
10.1515/cclm-2021-0687 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327092912 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327092912 | ||
| 003 | DE-627 | ||
| 005 | 20231225200019.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/cclm-2021-0687 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1090.xml |
| 035 | |a (DE-627)NLM327092912 | ||
| 035 | |a (NLM)34162025 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Salvagno, Gian Luca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Monitoring of the immunogenic response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers with Snibe SARS-CoV-2 S-RBD IgG chemiluminescent immunoassay |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.09.2021 | ||
| 500 | |a Date Revised 05.07.2022 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a CommentOn: Clin Chem Lab Med. 2021 Apr 14;59(8):1444-1452. - PMID 33855843 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antibodies | |
| 650 | 4 | |a immune response | |
| 650 | 4 | |a vaccination | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a N38TVC63NU |2 NLM | |
| 700 | 1 | |a Henry, Brandon M |e verfasserin |4 aut | |
| 700 | 1 | |a Pighi, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a De Nitto, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Gianfilippi, Gian Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Lippi, Giuseppe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry and laboratory medicine |d 1998 |g 59(2021), 10 vom: 27. Sept., Seite e377-e379 |w (DE-627)NLM095304118 |x 1437-4331 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2021 |g number:10 |g day:27 |g month:09 |g pages:e377-e379 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1515/cclm-2021-0687 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2021 |e 10 |b 27 |c 09 |h e377-e379 | ||